Article
Dr. Julie Atay discusses the two main objectives of her poster which evaluated the cost analysis of substituting Dabigatran for Warfarin.
Dr. Julie Atay discusses her poster, "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program," at ACC's 60th Annual Scientific Sessions. Dr. Atay provides a quick explanation about the two objectives her colleagues and she were evaluating: 1) The percentage of patients already on Warfarin who qualified to be on Dabigatran; and 2) The direct costs associated with switching patients from Warfarin to Dabigatran.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA